Cerebrospinal Fluid Proteomics For Identification Of α2-Macroglobulin As A Potential Biomarker To Monitor Pharmacological Therapeutic Efficacy In Dopamine Dictated Disease States Of Parkinson’s Disease And Schizophrenia

Cerebrospinal Fluid Proteomics For Identification Of α2-Macroglobulin As A Potential Biomarker To Monitor Pharmacological Therapeutic Efficacy In Dopamine Dictated Disease States Of Parkinson’s Disease And Schizophrenia

Ashish Kumar Gupta,1,* Ruchika Pokhriyal,1,* Mohd Imran Khan,1 Domada Ratna Kumar,1 Rishab Gupta,2 Rakesh Kumar Chadda,2 Rashmi Ramachandran,3 Vinay Goyal,4 Manjari Tripathi,4 Gururao Hariprasad1 1Department of Biophysics; 2Department of Psychiatry; 3Department of Anaesthesia; 4Department of Neurolo...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Gupta AK, Pokhriyal R, Khan MI, Kumar DR, Gupta R, Chadda RK, Ramachandran R, Goyal V, Tripathi M, Hariprasad G
Formato: article
Lenguaje:EN
Publicado: Dove Medical Press 2019
Materias:
Parkinson's disease
Schizophrenia
iTRAQ proteomics
dopamine
biomarkers
therapeutic efficacy
alpha 2 macroglobulin
Neurosciences. Biological psychiatry. Neuropsychiatry
RC321-571
Neurology. Diseases of the nervous system
RC346-429
Acceso en línea:https://doaj.org/article/aa0c375382c443d7b8415ff502d4a03b
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:aa0c375382c443d7b8415ff502d4a03b
record_format dspace
spelling oai:doaj.org-article:aa0c375382c443d7b8415ff502d4a03b2021-12-02T04:04:26ZCerebrospinal Fluid Proteomics For Identification Of α2-Macroglobulin As A Potential Biomarker To Monitor Pharmacological Therapeutic Efficacy In Dopamine Dictated Disease States Of Parkinson’s Disease And Schizophrenia1178-2021https://doaj.org/article/aa0c375382c443d7b8415ff502d4a03b2019-10-01T00:00:00Zhttps://www.dovepress.com/cerebrospinal-fluid-proteomics-for-identification-of-alpha2-macroglobu-peer-reviewed-article-NDThttps://doaj.org/toc/1178-2021Ashish Kumar Gupta,1,* Ruchika Pokhriyal,1,* Mohd Imran Khan,1 Domada Ratna Kumar,1 Rishab Gupta,2 Rakesh Kumar Chadda,2 Rashmi Ramachandran,3 Vinay Goyal,4 Manjari Tripathi,4 Gururao Hariprasad1 1Department of Biophysics; 2Department of Psychiatry; 3Department of Anaesthesia; 4Department of Neurology, All India Institute of Medical Sciences, New Delhi 110029, India*These authors contributed equally to this workCorrespondence: Gururao HariprasadDepartment of Biophysics, All India Institute of Medical Sciences, Ansari nagar, New Delhi 110029, IndiaTel +91 11 26594029Fax +91 11 26588663Email g.hariprasad@rediffmail.comAim: Parkinson’s disease and schizophrenia are clinical end points of dopaminergic deficit and excess, respectively, in the mid-brain. In accordance, current pharmacological interventions aim to restore normal dopamine levels, the overshooting of which culminates in adverse effects which results in psychotic symptoms in Parkinson’s disease and extra-pyramidal symptoms in schizophrenia. Currently, there are no laboratory assays to assist treatment decisions or help foresee these drug side-effect outcomes. Therefore, the aim was to discover a protein biomarker that had a varying linear expression across the clinical dopaminergic spectrum.Materials and methods: iTRAQ-based proteomic experiments along with mass spectrometric analysis was used for comparative proteomics using cerebrospinal fluid (CSF). CSF fluid was collected from 36 patients with Parkinson’s disease, 15 patients with urological diseases that served as neurological controls, and seven schizophrenic patients with hallucinations. Validation included ELISA and pathway analysis to highlight the varying expression and provide plausible molecular pathways for differentially expressed proteins in the three clinical phenotypes.Results: Protein profiles were delineated in CSF from Parkinson’s disease patients, neurological control and schizophrenia, respectively. Ten of the proteins that were identified had a linear relationship across the dopaminergic spectrum. α-2-Macroglobulin showed to be having high statistical significance on inter-group comparison on validation studies using ELISA.Conclusions: Non-gel-based proteomic experiments are an ideal platform to discover potential biomarkers that can be used to monitor pharmaco-therapeutic efficacy in dopamine-dictated clinical scenarios. α-2 Macroglobulin is a potential biomarker to monitor pharmacological therapy in Parkinson’s disease and schizophrenia.Keywords: Parkinson’s disease, schizophrenia, iTRAQ proteomics, dopamine, biomarkers, therapeutic efficacy, alpha-2-macroglobulinGupta AKPokhriyal RKhan MIKumar DRGupta RChadda RKRamachandran RGoyal VTripathi MHariprasad GDove Medical PressarticleParkinson's diseaseSchizophreniaiTRAQ proteomicsdopaminebiomarkerstherapeutic efficacyalpha 2 macroglobulinNeurosciences. Biological psychiatry. NeuropsychiatryRC321-571Neurology. Diseases of the nervous systemRC346-429ENNeuropsychiatric Disease and Treatment, Vol Volume 15, Pp 2853-2867 (2019)
institution DOAJ
collection DOAJ
language EN
topic Parkinson's disease
Schizophrenia
iTRAQ proteomics
dopamine
biomarkers
therapeutic efficacy
alpha 2 macroglobulin
Neurosciences. Biological psychiatry. Neuropsychiatry
RC321-571
Neurology. Diseases of the nervous system
RC346-429
spellingShingle Parkinson's disease
Schizophrenia
iTRAQ proteomics
dopamine
biomarkers
therapeutic efficacy
alpha 2 macroglobulin
Neurosciences. Biological psychiatry. Neuropsychiatry
RC321-571
Neurology. Diseases of the nervous system
RC346-429
Gupta AK
Pokhriyal R
Khan MI
Kumar DR
Gupta R
Chadda RK
Ramachandran R
Goyal V
Tripathi M
Hariprasad G
Cerebrospinal Fluid Proteomics For Identification Of α2-Macroglobulin As A Potential Biomarker To Monitor Pharmacological Therapeutic Efficacy In Dopamine Dictated Disease States Of Parkinson’s Disease And Schizophrenia
description Ashish Kumar Gupta,1,* Ruchika Pokhriyal,1,* Mohd Imran Khan,1 Domada Ratna Kumar,1 Rishab Gupta,2 Rakesh Kumar Chadda,2 Rashmi Ramachandran,3 Vinay Goyal,4 Manjari Tripathi,4 Gururao Hariprasad1 1Department of Biophysics; 2Department of Psychiatry; 3Department of Anaesthesia; 4Department of Neurology, All India Institute of Medical Sciences, New Delhi 110029, India*These authors contributed equally to this workCorrespondence: Gururao HariprasadDepartment of Biophysics, All India Institute of Medical Sciences, Ansari nagar, New Delhi 110029, IndiaTel +91 11 26594029Fax +91 11 26588663Email g.hariprasad@rediffmail.comAim: Parkinson’s disease and schizophrenia are clinical end points of dopaminergic deficit and excess, respectively, in the mid-brain. In accordance, current pharmacological interventions aim to restore normal dopamine levels, the overshooting of which culminates in adverse effects which results in psychotic symptoms in Parkinson’s disease and extra-pyramidal symptoms in schizophrenia. Currently, there are no laboratory assays to assist treatment decisions or help foresee these drug side-effect outcomes. Therefore, the aim was to discover a protein biomarker that had a varying linear expression across the clinical dopaminergic spectrum.Materials and methods: iTRAQ-based proteomic experiments along with mass spectrometric analysis was used for comparative proteomics using cerebrospinal fluid (CSF). CSF fluid was collected from 36 patients with Parkinson’s disease, 15 patients with urological diseases that served as neurological controls, and seven schizophrenic patients with hallucinations. Validation included ELISA and pathway analysis to highlight the varying expression and provide plausible molecular pathways for differentially expressed proteins in the three clinical phenotypes.Results: Protein profiles were delineated in CSF from Parkinson’s disease patients, neurological control and schizophrenia, respectively. Ten of the proteins that were identified had a linear relationship across the dopaminergic spectrum. α-2-Macroglobulin showed to be having high statistical significance on inter-group comparison on validation studies using ELISA.Conclusions: Non-gel-based proteomic experiments are an ideal platform to discover potential biomarkers that can be used to monitor pharmaco-therapeutic efficacy in dopamine-dictated clinical scenarios. α-2 Macroglobulin is a potential biomarker to monitor pharmacological therapy in Parkinson’s disease and schizophrenia.Keywords: Parkinson’s disease, schizophrenia, iTRAQ proteomics, dopamine, biomarkers, therapeutic efficacy, alpha-2-macroglobulin
format article
author Gupta AK
Pokhriyal R
Khan MI
Kumar DR
Gupta R
Chadda RK
Ramachandran R
Goyal V
Tripathi M
Hariprasad G
author_facet Gupta AK
Pokhriyal R
Khan MI
Kumar DR
Gupta R
Chadda RK
Ramachandran R
Goyal V
Tripathi M
Hariprasad G
author_sort Gupta AK
title Cerebrospinal Fluid Proteomics For Identification Of α2-Macroglobulin As A Potential Biomarker To Monitor Pharmacological Therapeutic Efficacy In Dopamine Dictated Disease States Of Parkinson’s Disease And Schizophrenia
title_short Cerebrospinal Fluid Proteomics For Identification Of α2-Macroglobulin As A Potential Biomarker To Monitor Pharmacological Therapeutic Efficacy In Dopamine Dictated Disease States Of Parkinson’s Disease And Schizophrenia
title_full Cerebrospinal Fluid Proteomics For Identification Of α2-Macroglobulin As A Potential Biomarker To Monitor Pharmacological Therapeutic Efficacy In Dopamine Dictated Disease States Of Parkinson’s Disease And Schizophrenia
title_fullStr Cerebrospinal Fluid Proteomics For Identification Of α2-Macroglobulin As A Potential Biomarker To Monitor Pharmacological Therapeutic Efficacy In Dopamine Dictated Disease States Of Parkinson’s Disease And Schizophrenia
title_full_unstemmed Cerebrospinal Fluid Proteomics For Identification Of α2-Macroglobulin As A Potential Biomarker To Monitor Pharmacological Therapeutic Efficacy In Dopamine Dictated Disease States Of Parkinson’s Disease And Schizophrenia
title_sort cerebrospinal fluid proteomics for identification of α2-macroglobulin as a potential biomarker to monitor pharmacological therapeutic efficacy in dopamine dictated disease states of parkinson’s disease and schizophrenia
publisher Dove Medical Press
publishDate 2019
url https://doaj.org/article/aa0c375382c443d7b8415ff502d4a03b
work_keys_str_mv AT guptaak cerebrospinalfluidproteomicsforidentificationofalpha2macroglobulinasapotentialbiomarkertomonitorpharmacologicaltherapeuticefficacyindopaminedictateddiseasestatesofparkinsonrsquosdiseaseandschizophrenia
AT pokhriyalr cerebrospinalfluidproteomicsforidentificationofalpha2macroglobulinasapotentialbiomarkertomonitorpharmacologicaltherapeuticefficacyindopaminedictateddiseasestatesofparkinsonrsquosdiseaseandschizophrenia
AT khanmi cerebrospinalfluidproteomicsforidentificationofalpha2macroglobulinasapotentialbiomarkertomonitorpharmacologicaltherapeuticefficacyindopaminedictateddiseasestatesofparkinsonrsquosdiseaseandschizophrenia
AT kumardr cerebrospinalfluidproteomicsforidentificationofalpha2macroglobulinasapotentialbiomarkertomonitorpharmacologicaltherapeuticefficacyindopaminedictateddiseasestatesofparkinsonrsquosdiseaseandschizophrenia
AT guptar cerebrospinalfluidproteomicsforidentificationofalpha2macroglobulinasapotentialbiomarkertomonitorpharmacologicaltherapeuticefficacyindopaminedictateddiseasestatesofparkinsonrsquosdiseaseandschizophrenia
AT chaddark cerebrospinalfluidproteomicsforidentificationofalpha2macroglobulinasapotentialbiomarkertomonitorpharmacologicaltherapeuticefficacyindopaminedictateddiseasestatesofparkinsonrsquosdiseaseandschizophrenia
AT ramachandranr cerebrospinalfluidproteomicsforidentificationofalpha2macroglobulinasapotentialbiomarkertomonitorpharmacologicaltherapeuticefficacyindopaminedictateddiseasestatesofparkinsonrsquosdiseaseandschizophrenia
AT goyalv cerebrospinalfluidproteomicsforidentificationofalpha2macroglobulinasapotentialbiomarkertomonitorpharmacologicaltherapeuticefficacyindopaminedictateddiseasestatesofparkinsonrsquosdiseaseandschizophrenia
AT tripathim cerebrospinalfluidproteomicsforidentificationofalpha2macroglobulinasapotentialbiomarkertomonitorpharmacologicaltherapeuticefficacyindopaminedictateddiseasestatesofparkinsonrsquosdiseaseandschizophrenia
AT hariprasadg cerebrospinalfluidproteomicsforidentificationofalpha2macroglobulinasapotentialbiomarkertomonitorpharmacologicaltherapeuticefficacyindopaminedictateddiseasestatesofparkinsonrsquosdiseaseandschizophrenia
_version_ 1718401451586224128

Ejemplares similares